Servier Showcases Robust Presence at ASCO 2019
Discover our news
Agios to Present Clinical Data from its IDH Program at ASCO
Servier Cuts Ribbon on New Boston Headquarters
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for Treatment of Newly Diagnosed AML with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients
Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
Servier Group Appoints David K. Lee as CEO of Servier Pharmaceuticals (U.S.)
Servier Acquires Shire’s Oncology Business to Gain Direct Commercial Access in the U.S.